Neuraptive Fortifies Leadership for Critical Commercialization Push

CHESTERBROOK, PA – June 08, 2026 – Neuraptive Therapeutics, a biotechnology firm on the cusp of a major transition, has announced two significant leadership appointments poised to steer the company through its next crucial phase. The additions of global pharmaceutical veteran Ulf Wiinberg to its Board of Directors and seasoned biotech financial executive William “Bill” MacKenzie as Senior Vice President – Finance signal a clear and decisive strategy: prepare for the commercial launch of its lead candidate, NTX-001.

The hires move Neuraptive beyond its research and development origins, equipping it with the strategic and operational firepower required to navigate the complex journey from clinical trials to market access. As the company focuses on addressing unmet needs in peripheral nerve injury, these appointments are a testament to its ambition and a calculated step toward transforming clinical promise into commercial reality.

“We are thrilled to welcome Bill and Ulf to the company,” said Bob Radie, Chairman of the Board and Chief Executive Officer of Neuraptive. “Bill’s deep financial expertise and leadership will be instrumental as we continue to progress NTX-001 toward commercialization, while Ulf’s global industry experience and strategic insight will provide immense value to our Board and leadership team.“

A Global Strategist Joins the Board

The appointment of Ulf Wiinberg brings a heavyweight of the global pharmaceutical industry into Neuraptive's inner circle. His career is a roadmap of leadership at the highest levels, marked by strategic transformations and successful product commercializations. As a new member of the Board, his role will be to provide the kind of high-level guidance that can only come from decades of experience steering large and small biopharma entities.

Mr. Wiinberg’s tenure as CEO of Lundbeck from 2008 to 2014 is particularly instructive. There, he guided the company's evolution from a primarily European player into a global force, a transition that involved diversifying its product portfolio beyond a single blockbuster model. He championed the development of multiple products targeting significant medical needs, a philosophy that aligns perfectly with Neuraptive’s focus on the specialized market of nerve repair. His prior experience as Worldwide President of Wyeth Consumer Healthcare and his role on Wyeth's Management Committee until its acquisition by Pfizer in 2009 further solidify his credentials in managing large-scale commercial operations and navigating major corporate transactions.

His current board positions underscore his continued influence and relevance in the industry. He serves as an independent director at UCB, a global biopharmaceutical company with a strong focus on neurology, providing direct parallels to Neuraptive's work. His directorships at MiNK Therapeutics, a clinical-stage company, and SIGRID Therapeutics, a commercial-stage health product company, demonstrate his versatility in guiding companies at various stages of their lifecycle. This breadth of experience is precisely what a company like Neuraptive needs as it prepares to make the leap to commercialization.

“I look forward to working collaboratively with my fellow directors and the management team at this exciting time in Neuraptive’s journey,” Mr. Wiinberg commented on his appointment, “as the company continues to advance its important work to address the unmet needs of physicians and patients impacted by peripheral nerve injuries.”

Fortifying Financial Operations for Market Entry

If Wiinberg provides the strategic map, William “Bill” MacKenzie is the architect of the financial engine needed to complete the journey. The promotion of MacKenzie from a consultant role to Senior Vice President – Finance is a critical move to build the robust operational infrastructure required for a product launch. Launching a new therapeutic is an immensely capital-intensive endeavor, and MacKenzie’s deep experience in biotech financial leadership is a direct answer to that challenge.

With over a decade of experience spanning public, private, and private equity-backed environments, MacKenzie is well-versed in the financial intricacies of the biotech world. His resume includes key roles at companies like Sage Therapeutics, a commercial-stage firm focused on brain health, and Zyla Life Sciences, a specialty pharmaceutical company. Critically, his background includes navigating the financial complexities surrounding multiple FDA-approved products and complex corporate restructurings. This hands-on experience is invaluable for a company preparing to manage the costs of manufacturing, marketing, sales force deployment, and reimbursement negotiations.

Notably, MacKenzie has been serving as a consultant and Head of Finance for Neuraptive since March 2025. This internal promotion suggests he has already proven his value and gained the trust of the leadership team. He is not starting from scratch; he is hitting the ground running with an intimate knowledge of Neuraptive's financial landscape and the specific needs of the NTX-001 program. His mandate to lead the enterprise finance function and develop the company's operational infrastructure places him at the center of building a sustainable commercial business.

The High Stakes of Peripheral Nerve Repair

The strategic fortification of Neuraptive's leadership is set against the backdrop of a significant and challenging medical field. Peripheral nerve injuries—damage to the nerves outside of the brain and spinal cord—can result from trauma, surgery, or disease, leading to chronic pain, loss of motor function, and a significant decrease in quality of life. The market has long been characterized by a substantial unmet need, with existing treatments often falling short of providing complete or satisfactory recovery.

This is the landscape Neuraptive aims to disrupt with NTX-001. While the company remains focused on its clinical progress, bringing in executives of this caliber is a strong indicator of its confidence in the therapeutic's potential. The decision to invest in top-tier commercial and financial talent suggests that the underlying science is strong and that the company is now focused on the final, and often most difficult, leg of the race: getting the product to patients. These hires are a signal to investors, partners, and the broader medical community that Neuraptive is building an organization capable of not just innovating in the lab, but executing in the marketplace.